Literature DB >> 15734424

Cyclosporine modulates the response to hypoxia-reoxygenation in pulmonary artery endothelial cells.

Alexander S Farivar1, Brendan C Mackinnon-Patterson, Andrew D Barnes, Anton S McCourtie, Michael S Mulligan.   

Abstract

BACKGROUND: Depletion of macrophages, neutrophils, or lymphocytes confers only partial protection against experimental lung reperfusion injury, suggesting that inflammatory responses in other cell types contribute to tissue injury. Endothelial cell activation has previously been shown to be critical to the development of ischemia-reperfusion injury in other vascular beds. Furthermore, cyclosporine (CSA) reduces in vivo lung reperfusion injury through attenuated secretion of proinflammatory mediators. These studies determined whether pulmonary artery endothelial cells (PAEC), subjected to hypoxia and reoxygenation, promote inflammation and whether CSA afforded any modulation of that response.
METHODS: Isolated rat PAEC were subjected in vitro to 2 hours hypoxia followed by up to 4 hours reoxygenation. Cells were pretreated with CSA or a cremaphor vehicle. Differences in activation of signaling kinases and transcription factors were assessed, as was cytokine-chemokine protein secretion.
RESULTS: There was significant signaling kinase (extracellular signal regulated kinase [ERK 1/2]) activation by 15 minutes reoxygenation, which was temporally associated with marked activation of the transcription factors nuclear factor kappa B (NFkappaB) and early growth response one (EGR-1). At 4 hours reoxygenation there were significant increases in chemokine protein secretion. The CSA decreased ERK 1/2 phosphorylation and significantly attenuated transcription factor transactivation at 15 minutes reoxygenation. The CSA was found to be selective in reducing cytokine-chemokine elaboration at 4 hours reoxygenation.
CONCLUSIONS: Hypoxia-reoxygenation induces ERK 1/2 phosphorylation, as well as transactivation of the transcription factors NFkappaB and EGR-1 in PAEC. Cyclosporine selectively reduces proinflammatory mediator secretion, likely by transcriptional regulation through NFkappaB and EGR-1. This is the first demonstration of ERK 1/2 inhibition afforded by CSA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15734424     DOI: 10.1016/j.athoracsur.2004.08.078

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  10 in total

Review 1.  Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy.

Authors:  Swati Bhattacharyya; Minghua Wu; Feng Fang; Warren Tourtellotte; Carol Feghali-Bostwick; John Varga
Journal:  Matrix Biol       Date:  2011-04-13       Impact factor: 11.583

Review 2.  Signaling regulation of fetoplacental angiogenesis.

Authors:  Kai Wang; Jing Zheng
Journal:  J Endocrinol       Date:  2011-11-21       Impact factor: 4.286

3.  Cyclosporin A inhibits CD11a/CD18 adhesion molecules due to inhibition of TNFalpha and IL-1 beta levels in the mouse model of pleurisy induced by carrageenan.

Authors:  Eduardo Monguilhott Dalmarco; Yara Santos Medeiros; Tânia Silvia Fröde
Journal:  Cell Adh Migr       Date:  2008-10-23       Impact factor: 3.405

4.  Protein phosphatase 3 differentially modulates vascular endothelial growth factor- and fibroblast growth factor 2-stimulated cell proliferation and signaling in ovine fetoplacental artery endothelial cells.

Authors:  Kai Wang; Yang Song; Dong-Bao Chen; Jing Zheng
Journal:  Biol Reprod       Date:  2008-05-28       Impact factor: 4.285

5.  Slit2 prevents neutrophil recruitment and renal ischemia-reperfusion injury.

Authors:  Swasti Chaturvedi; Darren A Yuen; Amandeep Bajwa; Yi-Wei Huang; Christiane Sokollik; Liping Huang; Grace Y Lam; Soumitra Tole; Guang-Ying Liu; Jerry Pan; Lauren Chan; Yaro Sokolskyy; Manoj Puthia; Gabriela Godaly; Rohan John; Changsen Wang; Warren L Lee; John H Brumell; Mark D Okusa; Lisa A Robinson
Journal:  J Am Soc Nephrol       Date:  2013-06-13       Impact factor: 10.121

6.  Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma.

Authors:  Swati Bhattacharyya; Shu-Jen Chen; Minghua Wu; Matthew Warner-Blankenship; Hongyan Ning; Gabriella Lakos; Yasuji Mori; Eric Chang; Chihiro Nihijima; Kazuhiro Takehara; Carol Feghali-Bostwick; John Varga
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

7.  Alveolar macrophage secretory products effect type 2 pneumocytes undergoing hypoxia-reoxygenation.

Authors:  Anton S McCourtie; Alexander S Farivar; Steven M Woolley; Heather E Merry; Patrick S Wolf; Brendan Mackinnon-Patterson; John C Keech; Elizabeth Fitzsullivan; Michael S Mulligan
Journal:  Ann Thorac Surg       Date:  2008-12       Impact factor: 4.330

Review 8.  Egr-1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis).

Authors:  Swati Bhattacharyya; Feng Fang; Warren Tourtellotte; John Varga
Journal:  J Pathol       Date:  2012-12-03       Impact factor: 7.996

9.  Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis.

Authors:  Swati Bhattacharyya; Jennifer L Sargent; Pan Du; Simon Lin; Warren G Tourtellotte; Kazuhiko Takehara; Michael L Whitfield; John Varga
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

10.  Parecoxib sodium alleviates ischemia reperfusion-induced pulmonary injury via inhibiting ERK/NF-κB and further activating the HIF-1α pathway.

Authors:  Jiantao Guo; Yiping Yang
Journal:  Immun Inflamm Dis       Date:  2022-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.